1. Home
  2. CUK vs BIIB Comparison

CUK vs BIIB Comparison

Compare CUK & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carnival Plc ADS ADS

CUK

Carnival Plc ADS ADS

HOLD

Current Price

$25.34

Market Cap

41.7B

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$184.64

Market Cap

27.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CUK
BIIB
Founded
1972
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.7B
27.1B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
CUK
BIIB
Price
$25.34
$184.64
Analyst Decision
Strong Buy
Buy
Analyst Count
21
27
Target Price
$35.57
$195.00
AVG Volume (30 Days)
2.8M
730.4K
Earning Date
03-27-2026
04-30-2026
Dividend Yield
0.62%
N/A
EPS Growth
N/A
N/A
EPS
N/A
8.79
Revenue
N/A
$9,890,600,000.00
Revenue This Year
$8.05
N/A
Revenue Next Year
$4.08
N/A
P/E Ratio
$16.36
$20.61
Revenue Growth
N/A
2.22
52 Week Low
$13.65
$110.04
52 Week High
$33.72
$202.41

Technical Indicators

Market Signals
Indicator
CUK
BIIB
Relative Strength Index (RSI) 41.74 48.67
Support Level $23.26 $181.24
Resistance Level $27.88 $191.60
Average True Range (ATR) 1.02 4.53
MACD -0.10 -0.70
Stochastic Oscillator 32.81 31.95

Price Performance

Historical Comparison
CUK
BIIB

About CUK Carnival Plc ADS ADS

Carnival is the largest global cruise company, with more than 90 ships in service. Its portfolio of brands includes Carnival Cruise Line, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard in the United Kingdom; Aida in Germany; and Costa Cruises in Southern Europe. It recently folded its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted nearly 14 million guests in 2025.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: